An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer (Voxel-Study) To assess the differences in progression-free survival at 6 months in subjects with KRAS wild-type metastatic colorectal cancer receiving second line treatment (after failure of a previous irinotecan ...

• Country None
• organs None
• Specialty None

Étude TITAN-RCC : étude de phase 2 visant à évaluer l’efficacité du nivolumab chez des patients ayant un carcinome des cellules rénales avancé ou métastatique. [essai clos aux inclusions] Le carcinome des cellules rénales est le type le plus fréquent de cancer du rein. Il peut prendre naissance à partir d’une cellule de différentes parties du rein et avec le temps il peut s’étendre aux...

• Country France
• organs Rein
• Specialty Immunothérapie - Vaccinothérapie

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) Studie zur Untersuchung einer Erhaltungstherapie durch Pembrolizumab nach einer platinbasierten Erstlinientherapie bei Patienten mit metastasierten, nicht-kleinzelligen Plattenepithelkarzinom der Lunge To investigate the efficacy of Pembrolizumab vs. placebo in terms of progression-free survival in patients with metastatic squamous, non-small cell lung cancer.

• Country None
• organs None
• Specialty None

EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study •To evaluate tolerability and safety of everolimus in second-line treatment of poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tum...

• Country None
• organs None
• Specialty None

A randomized, open-label, phase II maintenance study in patients with EGFR mutated, metastatic non-small-cell lung cancer who progressed after treatment with afatinib as first EGFR-targeting agent followed by a platinum-based induction chemotherapy Eine randomisierte, offene Phase II - Studie zur Fortführung der pan-ERBB Blockade nach einer platinbasierten Induktionschemotherapie bei Patienten mit metastasiertem, EGFR mutiertem, nicht-kleinzelligen Lungenkarzinom mit Progress nach Behandlung mit Afatinib als erste gegen den EGFR gerichtete Therapie To compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated non-small-cell lung cancer pr...

• Country None
• organs None
• Specialty None

An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer To demonstrate superiority of 5-fluorouracil, cisplatin and panitumumab over 5-fluorouracil and cisplatin alone in terms of overall survival in esophageal cancer

• Country None
• organs None
• Specialty None

A randomized phase II study in which therapy is either switched to Nivolumab after 3 months of treatment or therapy is continued with a tyrosine kinase inhibitor in patients with metastatic renal cell carcinoma (RCC) and disease control Eine randomisierte Phase II Studie zur Untersuchung einer frühzeitigen Therapieumstellung von Tyrosinkinase-Inhibitoren auf Nivolumab im Vergleich zu einer fortgesetzten Tyrosinkinase-Inhibitor Therapie in Patienten mit fortgeschrittenem oder metastasierten Nierenzellkarzinom und stabiler Erkrankung nach drei-monatiger Behandlung To assess the survival benefit from an early switch approach from sunitinib or pazopanib to nivolumab (anti-angiogenic to immunotherapy switch)

• Country None
• organs None
• Specialty None

Étude MATEO : étude de phase 2 randomisée visant à évaluer l’efficacité relative en termes de survie globale de la thérapie de désescalade de S-1 (Teysuno®) à la continuation de la chimiothérapie après une thérapie d’induction chez des patients ayant un cancer métastatique de l’oesophage ou de la jonction gastro-oesophagienne ou de l’estomac. Le cancer de l’estomac reste le deuxième cancer digestif en incidence en France avec environ 7000 nouveaux cas et 6000 décès par an. Son pronostic reste médiocre avec une survie globale à 10 ans d’env...

• Country France
• organs Estomac, Oesophage
• Specialty Chimiothérapie

A clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma To estimate the best ORR based on investigator assessment using RECIST 1.1 of the TITAN regimen in untreated (1st line) and pretreated (2nd line) subjects with IMDC intermediate and high risk, advance...

• Country None
• organs None
• Specialty None

A phase III study trying to find out whether proactive coaching will make feel patients feel better who take sunitinib for their kidney cancer which is either advanced, or has already spread. Eine Phase III Studie, die versucht herauszufinden, ob es Patienten mit fortgeschrittenem bzw. gestreutem Nierenkrebs, die Sunitinib nehmen, besser geht, wenn ihnen eine Begleitung durch einenTherapie-Coach angeboten wird The primary objective of the trial is to determine the effect of a 24-week concomitant coaching on patient reported outcomes of patients receiving standard treatment for mRCC with sunitinib. Das...

• Country None
• organs None
• Specialty None